Arrowhead Announces IND Filing To Begin Two Trials For Hepatitis
Shares of Arrowhead Research Corp (ARWR) jumped 10% today, after the news that the company has filed an IND to the FDA to begin testing two phase 2b trials using its drug ARC-520 in patients with the Hepatitis B virus. The company had run an initial phase 2a trial using ARC-520 against Hepatitis B using only a…